Detection of human immunodeficiency virus type 1 antiretroviral resistance mutations by high-density DNA probe arrays

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 2907-2912

  Gonzalez, R ^a   Masquelier, B ^b   Fleury, H ^b   Lacroix, B ^a   Troesch, A ^a   Vernet, G ^a   Telles, J N ^a  

^a BIOMÉRIEUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DNA; GAG PROTEIN; GLYCOPROTEIN GP 41; INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SILICON DIOXIDE;

AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; BIOTECHNOLOGY; CODON; DIAGNOSTIC TEST; DNA CLEAVAGE; DNA MICROARRAY; DNA PROBE; DRUG MONITORING; GAG CLEAVAGE SITE; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RESISTANCE; GENOTYPE; GENOTYPIC RESISTANCE TEST; HIGH DENSITY DNA PROBE ARRAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 SUBTYPE B; MAGNET; MAGNETIC SILICA PARTICLE; MAJOR CLINICAL STUDY; MOLECULAR HYBRIDIZATION; NESTED REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROTEINASE GENE; REVERSE TRANSCRIPTASE GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS GENE; VIRUS LOAD; VIRUS TYPING;

ANTI-HIV AGENTS; DNA PROBES; DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 3142685259     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.2907-2912.2004     Document Type: Article

References (32)

1. Barrie, K. A., E. E. Perez, S. L. Lamers, W. G. Farmerie, B. M. Dunn, J. W. Sleasman, and M. M. Goodenow. 1996. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219: 407-416.
2. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L. Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. Ioannidis, and T. C. Merigan. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F93.
3. Bernal-Mendez, E., C. Tora, I. Sothier, M. Kotera, A. Troesch, and A. Laayoun. 2003. Universal labeling chemistry for nucleic acid detection on DNA-arrays. Nucleosides Nucleotides Nucleic Acids 22:1647-1649.
4. Boom, R., C. J. Sol, M. M. Salimans, C. L. Jansen, P. M. Wertheim-van Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
5. Burke, D. S. 1997. Recombination in HIV: an important viral evolutionary strategy. Emerg. Infect. Dis. 3:253-259.
6. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
7. Cote, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
8. D'Aquila, R. T., J. M. Schapiro, F. Brun-Vezinet, B. Clotet, B. Conway, L. M. Demeter, R. M. Grant, V. A. Johnson, D. R. Kuritzkes, C. Loveday, R. W. Shafer, and D. D. Richman. 2002. Drug resistance mutations in HIV-1. Top. HIV Med. 10:11-15.
9. Domingo, E., L. Menendez-Arias, M. E. Quinones-Mateu, A. Holguin, M. Gutierrez-Rivas, M. A. Martinez, J. Quer, I. S. Novella, and J. J. Holland. 1997. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog. Drug Res. 48:99-128.
10. Durant, J., P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. A. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
11. Felsenstein, J. 1995. PHYLIP (phylogeny inference package), version 3.572c. Department of Genetics, University of Washington, Seattle.
12. Fodor, S. P., R. P. Rava, X. C. Huang, A. C. Pease, C. P. Holmes, and C. L. Adams. 1993. Multiplexed biochemical assays with biological chips. Nature 364:555-556.
13. Hanna, G. J., V. A. Johnson, D. R. Kuritzkes, D. D. Richman, J. Martinez-Picado, L. Sutton, J. D. Hazelwood, and R. T. D'Aquila. 2000. Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase. J. Clin. Microbiol. 38:2715-2721.
14. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schhleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
15. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
16. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
17. Koch, N., C. Tamalet, N. Tivoli, J. Fantini, and N. Yahi. 2001. Comparison of two commercial assays for the detection of insertion mutations of HIV-1 reverse transcriptase. J. Clin. Virol. 21:153-162.
18. Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat. Med. 2:753-759.
19. Lockhart, D. J., H. Dong, M. C. Byrne, M. T. Follettie, M. V. Gallo, M. S. Chee, M. Mittmann, C. Wang, M. Kobayashi, H. Horton, and E. L. Brown. 1996. Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat. Biotechnol. 14:1675-1680.
20. Lorenzi, P., M. Opravil, B. Hirschel, J. P. Chave, H. J. Furrer, H. Sax, T. V. Perneger, L. Perrin, L. Kaiser, and S. Yerly. 1999. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 13:F17-F21.
21. Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and Gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637.
22. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
23. Merel, P., I. Pellegrin, I. Garrigue, A. Caumont, M. H. Schrive, V. Birac, P. Bonot, and H. Fleury. 2001. Comparison of capillary electrophoresis sequencing with the new CEQ 2000 DNA analysis system (Beckman Coulter, Inc.) to conventional gel based systems for HIV drug resistance analysis. J. Virol. Methods 98:9-16.
24. Perelson, A. S., A. U. Neumann, M. Markowitz, J. M. Leonard, and D. D. Ho. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
25. Sato, H., Y. Tomita, K. Ebisawa, A. Hachiya, K. Shibamura, T. Shiino, R. Yang, M. Tatsumi, K. Gushi, H. Umeyama, S. Oka, Y. Takebe, and Y. Nagai. 2001. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase. J. Virol. 75:5604-5613.
26. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 2000. Resistance table: mutations in retroviral genes associated with drug resistance. Int. Antiviral News 8:65-91.
27. Shafer, R. W. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. 15:247-277.
28. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
29. Troesch, A., H. Nguyen, C. G. Miyada, S. Desvarenne, T. R. Gingeras, P. M. Kaplan, P. Cros, and C. Mabilat. 1999. Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays. J. Clin. Microbiol. 37:49-55.
30. Vahey, M., M. E. Nau, S. Barrick, J. D. Cooley, R. Sawyer, A. A. Sleeker, P. Vickerman, S. Bloor, B. Larder, N. L. Michael, and S. A. Wegner. 1999. Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. J. Clin. Microbiol. 37:2533-2537.
31. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
32. Zolopa, A. R., R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron. 1999. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann. Intern. Med. 131:813-821.